Logo

Jeffrey Bluestone, Vijay Kuchroo, Christoph Lengauer, Aviv Regev, Ramnik Xavier, Alexis Borisy, Jeff Ross, Anthony Philippakis, Maya Said, Jason Coloma, Susan O'Connor

May 15, 2018

Celsius Therapeutics has named its founders and leadership team.

The company's founders are Jeffrey Bluestone, president and CEO of the Parker Institute for Cancer Immunotherapy at the University of California, San Francisco; Vijay Kuchroo, professor of neurology at Harvard Medical School; Christoph Lengauer, venture partner at Third Rock Ventures; Aviv Regev, chair of the faculty, core member, and director of the Klarman Cell Observatory at the Broad Institute; and Ramnik Xavier, chief of gastroenterology at Massachusetts General Hospital. Lengauer is also Celsius' president.

Alexis Borisy, a partner at Third Rock Ventures, serves as executive chairman of the company's board of directors, and Lengauer is a board member. Regev is a board observer, along with Jeff Ross, cofounder of Syfr, and Anthony Philippakis, a venture partner at GV (formerly Google Ventures).

The firm's management team includes Maya Said, chief operating officer; Jason Coloma, chief business officer; and Susan O'Connor, chief people officer.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.